Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease [Yahoo! Finance]
Kyverna Therapeutics, Inc. (KYTX)
Company Research
Source: Yahoo! Finance
Kyverna Therapeutics will seek clearance of what could be the first marketed cell therapy for an autoimmune condition after the treatment succeeded in a pivotal trial in a progressive condition known as stiff person syndrome. According to Kyverna, four months after treatment with its therapy miv-cel, Phase 2 study participants had a median 46% improvement from the trial's start on a type of timed walking test. More than four-fifths had at least a 20% improvement, a threshold that's believed to be “clinically meaningful,” Kyverna said Monday. The therapy met its key secondary study goals as well. Kyverna said there were no “high-grade” cases of the immune or neurological side effects associated with treatments like miv-cel. There were Grade 3 or 4 instances of neutropenia, or low counts of a kind of white blood cell, but Kyverna said they were “manageable.” Kyverna will seek U.S. approval in the first half of next year. Kyverna has long been a front-runner in the race to transfo
Show less
Read more
Impact Snapshot
Event Time:
KYTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYTX alerts
High impacting Kyverna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYTX
News
- Kyverna Therapeutics (NASDAQ:KYTX) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Kyverna Therapeutics (NASDAQ:KYTX) was given a new $33.00 price target on by analysts at Morgan Stanley.MarketBeat
- Kyverna Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
- Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome [Seeking Alpha]Seeking Alpha
- Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome [Yahoo! Finance]Yahoo! Finance
KYTX
Earnings
- 11/12/25 - Beat
KYTX
Sec Filings
- 12/15/25 - Form 424B5
- 12/15/25 - Form 144
- 12/15/25 - Form 8-K
- KYTX's page on the SEC website